BACK

An Open-Label, 3-Arm, Multicenter, Randomized Phase 3 Study To Evaluate The Efficacy And Safety Of Elranatamab (Pf-06863135) Monotherapy And Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone In Participants With Relapsed/Refractory Multiple Myeloma Who Have Received At Least 2 Prior Lines Of Therapy Including Lenalidomide And A Proteasome Inhibitor (MAGNETISMM-5)